Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A1 | P13866 | 2/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 2/20 | 0.32 |
| ▸ | IRAK1 | P51617 | 3/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16374296 | 0.74 | EGFR (0.51) | — | |
| SCHEMBL16339503 | 0.72 | PDE1A (0.41) | — | |
| SCHEMBL16339171 | 0.71 | — | — | |
| SCHEMBL16339141 | 0.70 | — | — | |
| SCHEMBL16339318 | 0.68 | — | — | |
| SCHEMBL16339397 | 0.68 | CYP1A2 (0.32) | — | |
| SCHEMBL16339367 | 0.66 | MAPK1 (0.33) | — | |
| SCHEMBL16339995 | 0.65 | — | — | |
| SCHEMBL16339905 | 0.64 | EGFR (0.35) | — | |
| SCHEMBL30645341 | 0.64 | EGFR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052494-B1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | HOFFMANN LA ROCHE (CH) | 2018-12-26 | — | — | EP | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951064-B2 | Azaindazole compounds as inhibitors of T790M containing EGFR mutants | GENENTECH, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2016-09-08 | — | — | US | disclosed |
| EP-3052494-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | Genentech, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210354-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | GENENTECH, INC. (US) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257682-A1 | AZAINDAZOLE COMPOUNDS AS INHIBITORS OF T790M CONTAINING EGFR MUTANTS | EGFR, ERBB2, ERBB3 | SLC5A1 3372/4885MKNK1 262/4885MKNK2 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.